(NASDAQ: SEPN) Septerna's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Septerna's earnings in 2026 is -$58,809,000.On average, 10 Wall Street analysts forecast SEPN's earnings for 2026 to be -$45,669,676, with the lowest SEPN earnings forecast at -$96,094,371, and the highest SEPN earnings forecast at $11,753,225. On average, 8 Wall Street analysts forecast SEPN's earnings for 2027 to be -$78,475,726, with the lowest SEPN earnings forecast at -$116,278,577, and the highest SEPN earnings forecast at -$29,618,128.
In 2028, SEPN is forecast to generate -$88,599,171 in earnings, with the lowest earnings forecast at -$85,124,694 and the highest earnings forecast at -$91,205,029.